Humalog Mix50 (Insulin Lispro)

Humalog Mix50 is indicated for the management of blood glucose in adults with diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that includes diet and exercise.

• Treatment of type 1 diabetes mellitus when a rapid‑acting insulin component is required.
• Treatment of type 2 diabetes mellitus in patients needing both prandial and basal insulin coverage.
• Basal‑bolus insulin therapy to simplify injection schedules.
• Post‑prandial glucose control in combination with oral antidiabetic agents.
• Use in insulin‑treated patients who prefer a premixed formulation.

• Insulin lispro binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor's tyrosine kinase activity. This triggers intracellular signaling pathways that promote translocation of GLUT‑4 transporters to the cell membrane, increasing glucose uptake. In the liver, insulin lispro suppresses gluconeogenesis and glycogenolysis, thereby reducing hepatic glucose output and lowering blood glucose levels.

Adverse reactions to Humalog Mix50 can vary in frequency and severity.

Common

• Hypoglycaemia (low blood glucose)
• Injection site redness, swelling or itching
• Lipodystrophy (localized fat tissue changes)
• Weight gain
• Mild nausea

Serious

• Severe hypoglycaemia with loss of consciousness
• Allergic reactions such as urticaria, angioedema or anaphylaxis
• Hypersensitivity leading to respiratory distress
• Persistent edema or heart failure exacerbation
• Severe hypokalemia associated with insulin therapy

Humalog Mix50 should be used with careful monitoring and consideration of individual patient factors.

• Adjust dose when initiating therapy, during illness, or when changing diet or activity levels.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnant or breastfeeding women should consult a healthcare professional; category B indicates no proven risk in animal studies.
• Monitor for signs of hypoglycaemia, especially in elderly patients.
• Avoid use in patients with known hypersensitivity to insulin lispro or any excipients.
• Educate patients on proper injection technique and rotation of sites.

Humalog Mix50 can interact with several medications and substances that affect glucose metabolism.

Avoid

• Concurrent use of other rapid‑acting insulin products without dose adjustment.
• Beta‑blockers that may mask hypoglycaemia symptoms.
• High‑dose corticosteroids that increase blood glucose levels.
• MAO‑inhibitors that can potentiate hypoglycaemia.
• Alcohol excess, which can cause delayed hypoglycaemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk.
• Diuretics that may alter electrolyte balance.
• Thyroid hormones, which can modify insulin requirements.
• ACE inhibitors or ARBs, as they may affect renal function and insulin clearance.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal perfusion.